Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?
Diabetes & Metabolism Journal · 01.03.2025 · 49 (2) · 169-171
DOI: 10.4093/dmj.2025.0047 ↗Kurz gefasst
Editorial in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.03.2025. Verfasst von Tae Sun Park. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute…
Zitieren
APA
Park, T. S. (2025). Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?. Diabetes & Metabolism Journal, 49(2), 169-171. https://doi.org/10.4093/dmj.2025.0047
Vancouver
Park TS. Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?. Diabetes & Metabolism Journal. 2025;49(2):169-171. doi:10.4093/dmj.2025.0047
BibTeX
@article{Park2025,
author = {Park, Tae Sun},
title = {Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?},
journal = {Diabetes & Metabolism Journal},
year = {2025},
volume = {49},
number = {2},
pages = {169--171},
doi = {10.4093/dmj.2025.0047}
}
EUVIMED